Technical note: Phantom-based evaluation of CBCT dose calculation accuracy for use in adaptive radiotherapy.

Autor: Wessels C; Varian Medical Systems Imaging Laboratory, Daettwil, Switzerland., Strzelecki A; Varian Medical Systems Imaging Laboratory, Daettwil, Switzerland., Plamondon M; Varian Medical Systems Imaging Laboratory, Daettwil, Switzerland., Lehmann M; Varian Medical Systems Imaging Laboratory, Daettwil, Switzerland., Peterlik I; Varian Medical Systems Imaging Laboratory, Daettwil, Switzerland., Paysan P; Varian Medical Systems Imaging Laboratory, Daettwil, Switzerland., Nagy B; Varian Medical Systems Imaging Laboratory, Daettwil, Switzerland., Heinz A; Varian Medical Systems Imaging Laboratory, Daettwil, Switzerland., Seghers D; Varian Medical Systems Imaging Laboratory, Daettwil, Switzerland., Thompson S; Varian Medical Systems, Palo Alto, California, USA., Scheib SG; Varian Medical Systems Imaging Laboratory, Daettwil, Switzerland.
Jazyk: angličtina
Zdroj: Medical physics [Med Phys] 2024 Oct; Vol. 51 (10), pp. 7492-7499. Date of Electronic Publication: 2024 Aug 05.
DOI: 10.1002/mp.17325
Abstrakt: Background: High-quality 3D-anatomy of the day is needed for treatment plan adaptation in radiotherapy. For online x-ray-based CBCT workflows, one approach is to create a synthetic CT or to utilize a fan-beam CT with corresponding registrations. The former potentially introduces uncertainties in the dose calculation if deformable image registration is used. The latter can introduce burden and complexity to the process, the facility, and the patient.
Purpose: Using the CBCT of the day, acquired on the treatment device, for direct dose calculation and plan adaptation can overcome these limitations. This study aims to assess the accuracy of the calculated dose on the CBCT scans acquired on a Halcyon linear accelerator equipped with HyperSight.
Methods: HyperSight's new CBCT reconstruction algorithm includes improvements in scatter correction, HU calibration of the imager, and beam shape adaptation. Furthermore, HyperSight introduced a new x-ray detector. To show the effect of the implemented improvements, gamma comparisons of 2%/2 mm, 2%/1 mm, and 1%/1 mm were made between the dose distribution in phantoms calculated on the CBCT reconstructions and the simulation CT scans, considering this the standard of care. The resulting gamma passing rates were compared to those obtained with the Halcyon 3.0 reconstruction and hardware without HyperSight's technologies. Various anatomical phantoms for dosimetric evaluations on brain, head and neck, lung, breast, and prostate cases have been used in this study.
Results: The overall results demonstrated that HyperSight outperformed the Halcyon 3.0 version. Based on the gamma analysis, the calculated dose using HyperSight was closer to the CT scan-based doses than the calculated dose using iCBCT Halcyon 3.0 for most cases. Over all plans and gamma criteria, Halcyon 3.0 achieved an average passing rate of 92.9%, whereas HyperSight achieved 98.1%.
Conclusion: Using HyperSight CBCT images for direct dose calculation, for example, in (online) plan adaptation, seems feasible for the investigated cases.
(© 2024 American Association of Physicists in Medicine.)
Databáze: MEDLINE
Externí odkaz: